Press release
Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21
BOSTON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing
About this update from Compass Therapeutics, Inc.
[{"type":"text","content":"BOSTON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that updated results from the ongoing Phase 2 study of CTX-009 combined with paclitaxel in patients with biliary tract cancer (BTC) will be presented at a poster session of the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) taking place in San Francisco, CA January 19-21, 2023. Additional poster presentations by Compass include trials in progress posters for the ongoing Phase 2/3 study of CTX-009 combined with paclitaxel in patients with biliary tract cancers (BTC) and the ongoing Phase 2 study of CTX-009 in patients with metastatic colorectal cancer (CRC). Presentation Details Title: CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A Phase 2 study. Abstract #: 540 Poster #: C10 First Author: Do-Youn Oh; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of (South) Title: Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen. Abstract #: TPS640 Poster #: P9 Authors: Marilyn Fontaine, Sarah Pilgrim, Thomas Schuetz, Compass Therapeutics Title: Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. Abstract #: TPS281 Poster #: Q3 Authors: Marilyn Fontaine, Sarah Pilgrim, Thomas Schuetz, Compass Therapeutics Following conference presentation, the posters will be available in the Pipeline section of www.compasstherapeutics.com About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product ...